Your browser doesn't support javascript.
loading
Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell lymphoma.
Jain, Salvia; Jirau-Serrano, Xavier; Zullo, Kelly M; Scotto, Luigi; Palermo, Carmine F; Sastra, Stephen A; Olive, Kenneth P; Cremers, Serge; Thomas, Tiffany; Wei, Ying; Zhang, Yuan; Bhagat, Govind; Amengual, Jennifer E; Deng, Changchun; Karan, Charles; Realubit, Ronald; Bates, Susan E; O'Connor, Owen A.
Affiliation
  • Jain S; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
  • Jirau-Serrano X; Center for Lymphoid Malignancies, Columbia University Medical Center, New York, New York. Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York.
  • Zullo KM; Center for Lymphoid Malignancies, Columbia University Medical Center, New York, New York. Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York.
  • Scotto L; Center for Lymphoid Malignancies, Columbia University Medical Center, New York, New York. Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York.
  • Palermo CF; Department of Pathology and Cell Biology, Columbia University Medical Center, and Irving Institute for Clinical and Translational Research, New York, New York. Department of Medicine, Columbia University Medical Center, New York, New York. Department of Pathology and Cell Biology, Columbia Universit
  • Sastra SA; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York. Department of Pathology and Cell Biology, Columbia University Medical Center, and Irving Institute for Clinical and Translational Research, New York, New York. Department of Medicine, Columbia Univers
  • Olive KP; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York. Department of Pathology and Cell Biology, Columbia University Medical Center, and Irving Institute for Clinical and Translational Research, New York, New York. Department of Medicine, Columbia Univers
  • Cremers S; Department of Pathology and Cell Biology, Columbia University Medical Center, and Irving Institute for Clinical and Translational Research, New York, New York. Department of Medicine, Columbia University Medical Center, New York, New York. Department of Pathology and Cell Biology, Columbia Universit
  • Thomas T; Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York.
  • Wei Y; Department of Biostatistics, Columbia University Medical Center, New York, New York.
  • Zhang Y; Department of Biostatistics, Columbia University Medical Center, New York, New York.
  • Bhagat G; Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York.
  • Amengual JE; Center for Lymphoid Malignancies, Columbia University Medical Center, New York, New York. Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York. Department of Medicine, Columbia University Medical Center, New York, New York.
  • Deng C; Center for Lymphoid Malignancies, Columbia University Medical Center, New York, New York. Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York. Department of Medicine, Columbia University Medical Center, New York, New York.
  • Karan C; Department of Systems Biology High-Throughput Screening Facility, Columbia University Medical Center, New York, New York.
  • Realubit R; Department of Systems Biology High-Throughput Screening Facility, Columbia University Medical Center, New York, New York.
  • Bates SE; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
  • O'Connor OA; Center for Lymphoid Malignancies, Columbia University Medical Center, New York, New York. Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York. Department of Medicine, Columbia University Medical Center, New York, New York. oo2130@columbia.edu.
Clin Cancer Res ; 21(9): 2096-106, 2015 May 01.
Article in En | MEDLINE | ID: mdl-25677697
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Lymphoma, T-Cell / Xenograft Model Antitumor Assays / Disease Models, Animal Limits: Animals / Humans Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2015 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Lymphoma, T-Cell / Xenograft Model Antitumor Assays / Disease Models, Animal Limits: Animals / Humans Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2015 Document type: Article Country of publication: